EXPLORE!

GeoVaxLabs's vaccine shows promising results, targets two sites on the virus

  988 Views

eMediNexus    12 March 2022

A small pilot study, published in The Lancet Microbe on Wednesday, revealed promising results with an experimental vaccine against COVID-19, manufactured by GeoVax Labs Inc. The experimental vaccine GEO-CM04S1 was able to develop antibodies and induced immune responses which targeted the spike protein on the virus surface and the nucleocapsid of the virus.

Researchers from the City of Hope National Medical Center in Duarte, California said that the study included 56 volunteers who were administered the vaccine and around 94% of them developed antibodies against the spike and the nucleocapsid protein. T cells that protect against severe infection also responded well. Based on the success of the study, the vaccine has been scaled up to mid-stage clinical trials.

Two mid-stage trials of the vaccine are being carried out. The first trial was evaluating its safety and efficacy in immunosuppressed patients with blood cancer and the second study was evaluating its effectiveness as a booster dose in healthy individuals who had already been vaccinated with two doses of Moderna , Pfizer/BioNTech or Johnson & Johnson vaccines. The researchers would also check the levels of antibodies which would act against the Omicron variant. (Reuters, March 12, 2022)

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.